An innovation born out of frustration can give a huge boost to laboratory research into new treatments and medicines. Researchers Martijn Verdoes, theme Nanomedicine, and Bas van der Schoot, theme Cancer development and immune defense, together with Ferenc Scheeren, Leiden University Medical Centre, developed a technique to engineer and produce antibodies quickly, easily and cheaply. "This new technique will open up the field." The researchers published their results in the open access journal Science Advances.
Antibodies play a crucial and growing role in cancer treatment, immunotherapy and diagnostics. Antibodies recognise a cancer cell or another cell very specifically. Fundamental researchers also use antibodies in their research and in the development of new therapies. At present, however, producing and engineering antibodies is a lengthy, specialized and expensive process, which is consequently carried out mainly by biotechnology companies.
Easy, cheap and fast
This is a source of great frustration for researchers such as Scheeren and Verdoes. "We have all kinds of ideas for new research, but we were hampered because we couldn't engineer antibodies ourselves", Scheeren explains. The recent CRISPR-Cas technology offered a solution. "Using this new technique, we can easily, quickly and cheaply introduce genetic modifications in cells continuously producing large amounts of antibodies, so called hybridoma cells. This enabled us to produce large quantities of antibody variants to which we have made a variety of functional modifications, in a short period of time", says Bas van der Schoot, first author of the article.
The researchers believe that their discovery breaks open the field for the use of antibodies in the research phase. “Tinkering with an antibody can provide a great deal of information about its mode of actions”, says Verdoes. “We can also introduce completely new elements and learn step by step how to make the antibody increasingly effective for clinical use. Using our technique, this can now be done at low cost and in a short period of time."
Several fellow-researchers have already responded enthusiastically, according to Scheeren. "Almost every laboratory able to culture cells – and there are many of them – can use this effective technique." The researchers therefore make their reagents publicly available on the addgene.com website.
This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 679921).
Related news items
Laurens Verscheijden awarded doctorate degree 'cum laude'19 January 2022
Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.read more
Aerobe exercise has a positive effect on brain function in Parkinson's disease patients18 January 2022
Radboudumc researchers have shown that the brain function of patients with Parkinson's disease improved with regular exercise, which seems to strengthen the connections between different brain areas, while inhibiting brain shrinkage.read more
Last call for nominations for the RIHS Awards 2021 Deadline for submission is 25 January 202218 January 2022
RIHS researchers are invited to propose candidates for the RIHS PhD Award, the Societal Impact Award, the Science Award, the Supervisor of the Year Award, and the RIHS Patient Involvement Award.read more
Rogier Kievit and Geert Litjens both receive ERC Starting Grant of 1.5 million euros Board of Directors congratulates researchers on top grant13 January 2022
Researchers Rogier Kievit and Geert Litjens were today festively welcomed by the Board of Directors, because of the ERC Starting Grants they both received. With these European top grants, they can each design an ambitious research project and put together their own research group.read more
Improved AI will boost cancer research and cancer care Geert Litjens receives ERC Starting Grant13 January 2022
Geert Litjens from Radboud university medical center has received a European Research Council (ERC) Starting Grant.read more
Understanding fluctuation variation in cognitive abilities may provide insight into lifelong learning Rogier Kievit recieves ERC Starting Grant13 January 2022
Rogier Kievit from Radboud university medical center has received a European Research Council (ERC) Starting Grant.read more